Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 13

Are blood eosinophils a prime-time biomarker for COPD management decisions?

Authors Tsiligianni I, Kaplan AG

Received 25 January 2018

Accepted for publication 5 April 2018

Published 12 June 2018 Volume 2018:13 Pages 1889—1891


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 1

Editor who approved publication: Dr Richard Russell

Ioanna Tsiligianni,1 Alan G Kaplan2

1Department of Social Medicine, Faculty of Medicine, University of Crete, Heraklion, Greece; 2Family Physician Airways Group of Canada, University of Toronto, Toronto, ON, Canada
COPD is a preventable and treatable disease with patients showing a great disease heterogeneity with respect to risk of exacerbations, symptomatology and health status. Dual bronchodilation has been suggested by the recent Global Initiative for Obstructive Lung Disease guideline as the cornerstone of treatment for COPD, limiting the value of inhaled corticosteroids (ICS) only for patients exacerbating on dual bronchodilators or possibly in those with frequent exacerbations.1 Elevated blood eosinophil count has been suggested as a useful biomarker to guide treatment decisions as its finding is considered consistent with a good ICS response to treatment,2–4 although this has been questioned in a recent post hoc analysis of the FLAME study.5 The practicing physician wants a biomarker to assess the risk of exacerbations and guide treatment accordingly; are blood eosinophils the answer? 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]